Abbott Will Cover Repeat Testing For Up To 1.5 Mil. Recalled Gonorrhea Kits
This article was originally published in The Gray Sheet
Executive Summary
Abbott's withdrawal of 1.5 mil. gonorrhea assays from the market, detailed by FDA in an Aug. 30 Class I recall notice, is not expected to have a significant financial impact, the firm says